Sirolimus, also can be addressed as rapamycin. In the month of September 1999, rapamycin got the approval by the US FDA (Food and Drug Administration). It is marketed under the brand name Rapamune by Pfizer (formerly by Wyeth).
Sirolimus specifically is a macrolide compound that is introduced to coat coronary stents, prevent organ transplant rejection and treat a rare lung disease named lymphangioleiomyomatosis.
This agent has immunosuppressant functions in humans and is quite useful in order to prevent the rejection of kidney transplants. It blocks the activation of T & B cells in order to reduce their sensitivity to interleukin-2 (IL-2) through inhibition (mTOR).
Sign in to leave a comment.